Syndax Pharmaceuticals INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Syndax Pharmaceuticals, Inc. reported significant revenue growth in Q3 2025 driven by its newly commercialized products, Revuforj and Niktimvo, alongside a second FDA approval for Revuforj.
NASDAQ
Syndax Pharmaceuticals reported significant revenue growth from its newly launched cancer therapies, Revuforj and Niktimvo, in Q2 2025, though net losses increased due to higher operating expenses.
NASDAQ
Syndax Pharmaceuticals announces its Q1 2025 financial results, highlighting revenue growth from the successful launches of Revuforj and Niktimvo.
NASDAQ
Syndax Pharmaceuticals reports a net loss of $84.1 million for the third quarter of 2024, while achieving a key milestone with the FDA approval of Niktimvo and advancing its revumenib program.
NASDAQ
Syndax Pharmaceuticals reports a net loss of $140.5 million for the first half of 2024, while advancing its clinical programs for revumenib and axatilimab.
NASDAQ
Syndax Pharmaceuticals reported a net loss of $72.4 million for the first quarter of 2024, while also highlighting progress in the development of its key drug candidates, revumenib and axatilimab.